PDF(Pubmed)
Abstract：
OBJECTIVE: High-grade gliomas (HGGs) are highly malignant, aggressive, and have a high incidence and mortality rate. The aim of this study was to investigate survival outcomes and prognostic factors in patients with HGGs.
METHODS: In this retrospective study, a total of 159 patients with histologically confirmed HGGs were included. The recruitment period was from January 2011 to December 2019. We evaluated patient demographic data, tumor characteristics, treatment methods, immunocytochemistry results, overall survival (OS) time, and progression-free survival (PFS) time using Kaplan-<>Meier survival analysis with log-rank testing. Additionally, we employed Cox regression analysis to identify independent factors associated with survival outcomes.
RESULTS: Kaplan-Meier survival analysis revealed that the 1-, 2-, and 5-years OS rates were 81.8%, 50.3%, and 12.6%, respectively. Similarly, the 1-, 2-, and 5-years PFS rates were 50.9%, 22.4%, and 3.1%, respectively. The median OS duration was 35.0 months. The univariate analysis indicated that postoperative pathological classification, grade, and age were significantly associated with patient outcomes (p < 0.01). Among the patients, 147 received concurrent chemoradiotherapy, while 12 did not. The immunohistochemical markers of ki-67, MGMT, IDH1R132H, and p53 demonstrated statistically significant differences in their prognostic impact (p = 0.001, p = 0.020, p = 0.003, and p = 0.021, respectively). In conclusion, we found that grades, age, pathological classification, ki-67, MGMT, and IDH1R132H expression were statistically significantly associated with PFS (p < 0.01, p = 0.004, p = 0.003, p = 0.001, p = 0.036, and p = 0.028). Additionally, immunohistochemical expressions of TRIB3 and AURKA were significantly higher in patients with shorter survival (p = 0.015 and p = 0.023).
CONCLUSIONS: Tumor grade and the use of concurrent chemoradiotherapy after surgery were independent prognostic factors that significantly influenced patient survival. Additionally, tumor grade and MGMT expression were found to be independent factors affecting progression-free survival (PFS). Notably, the expression of TRIB3 and AURKA was higher in patients with poor survival outcomes.
METHODS: In this retrospective study, a total of 159 patients with histologically confirmed HGGs were included. The recruitment period was from January 2011 to December 2019. We evaluated patient demographic data, tumor characteristics, treatment methods, immunocytochemistry results, overall survival (OS) time, and progression-free survival (PFS) time using Kaplan-<>Meier survival analysis with log-rank testing. Additionally, we employed Cox regression analysis to identify independent factors associated with survival outcomes.
RESULTS: Kaplan-Meier survival analysis revealed that the 1-, 2-, and 5-years OS rates were 81.8%, 50.3%, and 12.6%, respectively. Similarly, the 1-, 2-, and 5-years PFS rates were 50.9%, 22.4%, and 3.1%, respectively. The median OS duration was 35.0 months. The univariate analysis indicated that postoperative pathological classification, grade, and age were significantly associated with patient outcomes (p < 0.01). Among the patients, 147 received concurrent chemoradiotherapy, while 12 did not. The immunohistochemical markers of ki-67, MGMT, IDH1R132H, and p53 demonstrated statistically significant differences in their prognostic impact (p = 0.001, p = 0.020, p = 0.003, and p = 0.021, respectively). In conclusion, we found that grades, age, pathological classification, ki-67, MGMT, and IDH1R132H expression were statistically significantly associated with PFS (p < 0.01, p = 0.004, p = 0.003, p = 0.001, p = 0.036, and p = 0.028). Additionally, immunohistochemical expressions of TRIB3 and AURKA were significantly higher in patients with shorter survival (p = 0.015 and p = 0.023).
CONCLUSIONS: Tumor grade and the use of concurrent chemoradiotherapy after surgery were independent prognostic factors that significantly influenced patient survival. Additionally, tumor grade and MGMT expression were found to be independent factors affecting progression-free survival (PFS). Notably, the expression of TRIB3 and AURKA was higher in patients with poor survival outcomes.
摘要：
目的：高级别胶质瘤（HGG）是高度恶性的，侵略性,发病率和死亡率都很高。这项研究的目的是调查HGs患者的生存结果和预后因素。
方法：在这项回顾性研究中，共纳入了159例经组织学证实的HGG患者.招聘期为2011年1月至2019年12月。我们评估了患者的人口统计数据，肿瘤特征，治疗方法,免疫细胞化学结果，总生存期（OS）时间，和无进展生存期（PFS）时间使用Kaplan-<>Meier生存分析与对数秩检验。此外,我们采用Cox回归分析来确定与生存结局相关的独立因素.
结果：Kaplan-Meier生存分析显示，1-，2-,5年OS率为81.8%，50.3%,12.6%，分别。同样，1-,2-,5年PFS率为50.9%，22.4%,和3.1%，分别。中位OS持续时间为35.0个月。单因素分析显示术后病理分型,grade,和年龄与患者预后显著相关(p<0.01)。在患者中,147人接受同步放化疗，12没有。ki-67、MGMT、IDH1R132H,和p53在预后影响方面表现出统计学上的显着差异（分别为p=0.001，p=0.020，p=0.003和p=0.021）。总之,我们发现成绩，年龄,病理分类，ki-67,MGMT,和IDH1R132H表达与PFS有统计学意义(p<0.01,p=0.004,p=0.003,p=0.001,p=0.036,p=0.028)。此外,在生存期较短的患者中，TRIB3和AURKA的免疫组织化学表达显着升高（p=0.015和p=0.023）。
结论：肿瘤分级和术后同步放化疗是影响患者生存的独立预后因素。此外,肿瘤分级和MGMT表达是影响无进展生存期(PFS)的独立因素.值得注意的是,在生存结局较差的患者中,TRIB3和AURKA的表达较高.
方法：在这项回顾性研究中，共纳入了159例经组织学证实的HGG患者.招聘期为2011年1月至2019年12月。我们评估了患者的人口统计数据，肿瘤特征，治疗方法,免疫细胞化学结果，总生存期（OS）时间，和无进展生存期（PFS）时间使用Kaplan-<>Meier生存分析与对数秩检验。此外,我们采用Cox回归分析来确定与生存结局相关的独立因素.
结果：Kaplan-Meier生存分析显示，1-，2-,5年OS率为81.8%，50.3%,12.6%，分别。同样，1-,2-,5年PFS率为50.9%，22.4%,和3.1%，分别。中位OS持续时间为35.0个月。单因素分析显示术后病理分型,grade,和年龄与患者预后显著相关(p<0.01)。在患者中,147人接受同步放化疗，12没有。ki-67、MGMT、IDH1R132H,和p53在预后影响方面表现出统计学上的显着差异（分别为p=0.001，p=0.020，p=0.003和p=0.021）。总之,我们发现成绩，年龄,病理分类，ki-67,MGMT,和IDH1R132H表达与PFS有统计学意义(p<0.01,p=0.004,p=0.003,p=0.001,p=0.036,p=0.028)。此外,在生存期较短的患者中，TRIB3和AURKA的免疫组织化学表达显着升高（p=0.015和p=0.023）。
结论：肿瘤分级和术后同步放化疗是影响患者生存的独立预后因素。此外,肿瘤分级和MGMT表达是影响无进展生存期(PFS)的独立因素.值得注意的是,在生存结局较差的患者中,TRIB3和AURKA的表达较高.
